Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Regular cancer screenings can detect the disease in its earliest and most treatable stages, yet many people continue to delay ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

A new study suggests that many women with early-stage breast cancer may not need radiation after a mastectomy, thanks to ...

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

Guidance enhancement using 3D augmented reality and artificial intelligence technologies have recently been introduced for robot-assisted radical prostatectomy.

5-year overall survival (OS) rate for stereotactic body radiation ... which reported a recurrence-free rate of 67% - 100% in lung cancer patients treated with IceCure's cryoablation system. According ...

Icecure Medical ( ($ICCM) ) has shared an update. On November 3, 2025, IceCure Medical announced the successful results of an independent study ...

A Northwestern team transformed a common chemotherapy drug into a powerful, targeted cancer therapy using spherical nucleic ...

After beating lung cancer, a Cleveland Clinic employee shares his story with patients facing their own health battles.

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Lutetium Lu 177 vipivotide tetraxetan combined with ARPI and ADT improved rPFS in PSMA-positive mHSPC patients compared to ARPI and ADT alone. Lutetium Lu 177 vipivotide tetraxetan significantly ...